[go: up one dir, main page]

WO2019234677A3 - Biomarqueurs pour un diagnostic précoce non invasif de maladies infectieuses - Google Patents

Biomarqueurs pour un diagnostic précoce non invasif de maladies infectieuses Download PDF

Info

Publication number
WO2019234677A3
WO2019234677A3 PCT/IB2019/054716 IB2019054716W WO2019234677A3 WO 2019234677 A3 WO2019234677 A3 WO 2019234677A3 IB 2019054716 W IB2019054716 W IB 2019054716W WO 2019234677 A3 WO2019234677 A3 WO 2019234677A3
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
early diagnosis
infectious diseases
invasive early
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2019/054716
Other languages
English (en)
Other versions
WO2019234677A2 (fr
Inventor
Luisa Pecorari
Gianfranco Mario Emilio GILARDELLI
Anna IANNONE
Elena Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP19736814.5A priority Critical patent/EP3803393A2/fr
Publication of WO2019234677A2 publication Critical patent/WO2019234677A2/fr
Publication of WO2019234677A3 publication Critical patent/WO2019234677A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4713—Plasma globulins, lactoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

La présente invention concerne une méthode de diagnostic précoce non invasif de maladies infectieuses, en particulier la mammite, chez un sujet, par la détermination, dans un échantillon de liquide biologique, en particulier du liquide lacrymal, en provenance dudit sujet, de la quantité d'au moins deux biomarqueurs choisis parmi un panel, et la comparaison desdites quantités avec les valeurs de référence correspondantes. La variation combinée de la quantité de chacun desdits biomarqueurs par rapport à la valeur de référence correspondante indique l'apparition de la maladie infectieuse.
PCT/IB2019/054716 2018-06-08 2019-06-06 Biomarqueurs pour un diagnostic précoce non invasif de maladies infectieuses Ceased WO2019234677A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19736814.5A EP3803393A2 (fr) 2018-06-08 2019-06-06 Biomarqueurs pour un diagnostic précoce non invasif de maladies infectieuses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000006170 2018-06-08
IT102018000006170A IT201800006170A1 (it) 2018-06-08 2018-06-08 Biomarcatori per la diagnosi precoce non invasiva di patologie infettive

Publications (2)

Publication Number Publication Date
WO2019234677A2 WO2019234677A2 (fr) 2019-12-12
WO2019234677A3 true WO2019234677A3 (fr) 2020-03-12

Family

ID=63579612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/054716 Ceased WO2019234677A2 (fr) 2018-06-08 2019-06-06 Biomarqueurs pour un diagnostic précoce non invasif de maladies infectieuses

Country Status (3)

Country Link
EP (1) EP3803393A2 (fr)
IT (1) IT201800006170A1 (fr)
WO (1) WO2019234677A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120045778A1 (en) * 2010-08-23 2012-02-23 The Ohio State University Research Foundation Elisa for haptoglobin-matrix metalloproteinase 9 complex as a diagnostic test for conditions including acute inflammation
WO2013014669A1 (fr) * 2011-07-24 2013-01-31 Carmel-Haifa University Economic Corp. Fragments de lactoferrine et leur utilisation
CA2988833A1 (fr) * 2015-06-10 2016-12-15 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Procede et dispositif pour surveiller l'etat de sante de vaches laitieres

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120045778A1 (en) * 2010-08-23 2012-02-23 The Ohio State University Research Foundation Elisa for haptoglobin-matrix metalloproteinase 9 complex as a diagnostic test for conditions including acute inflammation
WO2013014669A1 (fr) * 2011-07-24 2013-01-31 Carmel-Haifa University Economic Corp. Fragments de lactoferrine et leur utilisation
CA2988833A1 (fr) * 2015-06-10 2016-12-15 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Procede et dispositif pour surveiller l'etat de sante de vaches laitieres

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOEHMER J L ET AL: "Proteomic Analysis of Differentially Expressed Proteins in Bovine Milk During Experimentally Induced Escherichia coli Mastitis", JOURNAL OF DAIRY SCIENCE, AMERICAN DAIRY SCIENCE ASSOCIATION, US, vol. 91, no. 11, 1 November 2008 (2008-11-01), pages 4206 - 4218, XP026955103, ISSN: 0022-0302, [retrieved on 20081101] *
CARLA DUARTE ET AL: "Technological advances in bovine mastitis diagnosis: an overview", JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION, vol. 27, no. 6, 1 January 2015 (2015-01-01), pages 665 - 672, XP055450209 *
CARLO DE OLIVEIRA MARTINS ET AL: "Distinct Mitral Valve Proteomic Profiles in Rheumatic Heart Disease and Myxomatous Degeneration", CLINICAL MEDICINE INSIGHTS: CARDIOLOGY, vol. 8, 1 January 2014 (2014-01-01), XP055524234, ISSN: 1179-5468, DOI: 10.4137/CMC.S17622 *
JINMING HUANG ET AL: "iTRAQ-proteomics and bioinformatics analyses of mammary tissue from cows with clinical mastitis due to natural infection with Staphylococci aureus", BMC GENOMICS, BIOMED CENTRAL, vol. 15, no. 1, 2 October 2014 (2014-10-02), pages 839, XP021199100, ISSN: 1471-2164, DOI: 10.1186/1471-2164-15-839 *
KALMUS P ET AL: "Milk haptoglobin, milk amyloid A, and N-acetyl-[beta]-D-glucosaminidase activity in bovines with naturally occurring clinical mastitis diagnosed with a quantitative PCR test", JOURNAL OF DAIRY SCIENCE, AMERICAN DAIRY SCIENCE ASSOCIATION, US, vol. 96, no. 6, 1 June 2013 (2013-06-01), pages 3662 - 3670, XP002759760, ISSN: 0022-0302, [retrieved on 20130330], DOI: 10.3168/JDS.2012-6177 *
SHOAIB ASHRAF ET AL: "Clumping factor A of Staphylococcus aureus interacts with AnnexinA2 on mammary epithelial cells", SCIENTIFIC REPORTS, vol. 7, no. 1, 19 January 2017 (2017-01-19), XP055524226, DOI: 10.1038/srep40608 *

Also Published As

Publication number Publication date
WO2019234677A2 (fr) 2019-12-12
IT201800006170A1 (it) 2019-12-08
EP3803393A2 (fr) 2021-04-14

Similar Documents

Publication Publication Date Title
WO2020123316A3 (fr) Procédés de détermination d'un emplacement d'un analyte biologique dans un échantillon biologique
WO2018209361A3 (fr) Diagnostic de cancer précoce universel
WO2018007872A9 (fr) Biomarqueurs d'une affection abdominale inflammatoire
CA3010517A1 (fr) Procede d'evaluation de l'etat de sante d'une personne
WO2015193325A3 (fr) Céramides et leur utilisation dans le diagnostic de maladies cardiovasculaires
BR112016018116A2 (pt) anticorpo e sequências específicos para e. coli, preparação farmacêutica ou para diagnóstico compreendendo os mesmos, uso do anticorpo para tratar infecção por e. coli e diagnosticar a doença, ácido nucleico que codifica o anticorpo, um cassete de expressão, plasmídeo ou célula hospedeira compreendendo o mesmo, e método de produção
WO2018038352A3 (fr) Biomarqueur d'auto-anticorps permettant de diagnostiquer la démence et méthode de diagnostic de la démence utilisant celui-ci
WO2019126556A3 (fr) Test théragnostique pour le traitement antifongique de maladies inflammatoires
JP2017508144A5 (fr)
WO2017165766A3 (fr) Biomarqueurs de protéinopathies et utilisations associées
WO2020213969A3 (fr) Biomarqueur pour diagnostiquer un dysfonctionnement des cellules endothéliales cornéennes
MX2019012439A (es) Herramienta de diagnostico para determinar el borramiento del proceso del pie del podocito.
WO2010138610A3 (fr) Nouveaux sites de phosphorylation de la desmine utiles dans le diagnostic de maladies cardiaques et l'intervention dans le cadre de ces maladies
WO2015200887A3 (fr) Procédé permettant de diagnostiquer une forme infraclinique et clinique du rejet aigu par analyse de séries de gènes prédictifs
WO2019234677A3 (fr) Biomarqueurs pour un diagnostic précoce non invasif de maladies infectieuses
WO2015006657A3 (fr) Méthode de diagnostic et de pronostic du cancer
WO2020115270A3 (fr) Biomarqueur
WO2018236134A3 (fr) Procédé et kit pour le diagnostic de maladies liées à une faiblesse musculaire à l'aide d'un biomarqueur sanguin
EP3492607A3 (fr) Miarns urinaires pour le diagnostic in vitro du cancer de la vessie
BR112022012010A2 (pt) Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
WO2020086810A3 (fr) Procédés d'utilisation d'histatine pour diagnostiquer et traiter la maladie de l'oeil sec ou d'autres maladies oculaires
WO2014197460A8 (fr) Procédés de diagnostic et de traitement de la bicuspidie valvulaire aortique et/ou d'aortopathies
CA2984732C (fr) Methode de diagnostic in vitro de la maladie d'alzheimer, fondee sur le taux de redox d'albumine dans le liquide cerebrospinal
WO2017059276A8 (fr) Procédés thérapeutiques et diagnostiques pour des maladies autoimmunes et/ou des inflammations
WO2015158608A3 (fr) Diagnostic d'une néphropathie chronique par analyse quantitative de modifications post-translationnelles des protéines plasmatiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19736814

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019736814

Country of ref document: EP

Effective date: 20210111